isabelobrien, Author at European Medical Journal - Page 15 of 66

Gold coins on blue background

UK to raise branded drug repayment rate to over 30%

The UK will hike statutory payment rates for branded drugs to over 30% in 2025, far surpassing other European markets and raising concerns.

Education or promotion: What wins with HCPs?

When every second of a healthcare professional’s time counts, what content truly earns their attention – disease awareness or product promotion?

Yacin Marzouki

Yacin Marzouki on disrupting the traditional omnichannel model

Omnichannel engagement expert Yacin Marzouki joins the show to share his strategies on how to make omnichannel work for both pharmaceutical companies and healthcare professionals.

Social media interaction icons

Social media key to Gen Z pharma hires, says ABPI

According to new research from the ABPI, pharma companies need to modernise their outreach strategies.

Rafael Fonseca

Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies

Rafael Fonseca, Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA

GSK’s Dheepa Chari on the evolving sphere of scientific communication

Dheepa Chari joins EMJ GOLD to discuss her career path, AI in pharma and the future of scientific communication.

Illustration of kidneys

Vantive to invest $1bn in digital kidney care therapies

Vantive has announced the five-year, major investment to expand its R&D and manufacturing capabilities.

Two men walking on arrows

Sanofi to acquire Blueprint in $9.1bn deal

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

Two illustrated hands, one holding money, the other a first aid box

King’s Fund sheds light on access to medicine in UK

The King’s Fund in the UK has released an updated explainer on the availability of new medicines in the UK’s NHS.

Stack of cartoon money

Kyron.bio lands €5.5m to refine biologic drug design

The Paris biotech aims to improve biologic drugs by mastering glycan control, aiming for safer, more effective therapies.